{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Linsitinib",
  "nciThesaurus": {
    "casRegistry": "867160-71-2",
    "chebiId": "",
    "chemicalFormula": "C26H23N5O",
    "definition": "An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.",
    "fdaUniiCode": "15A52GPT8T",
    "identifier": "C70982",
    "preferredName": "Linsitinib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C1967"
    ],
    "synonyms": [
      "Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, cis-",
      "IGF-1R inhibitor OSI-906",
      "LINSITINIB",
      "Linsitinib",
      "OSI-906",
      "OSI-906AA",
      "cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol"
    ]
  }
}